Vertex Pharmaceuticals VRTX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenues, net by Product | ||||||
| ALYFTREK | $424.4M+687% | $380.1M— | $247M— | $156.8M— | $53.9M— | |
| CASGEVY | $42.9M+202% | $54.3M+579% | $16.9M+745% | $30.4M— | $14.2M— | |
| JOURNAVX | $29M+2,131% | $26.7M— | $19.6M— | $12M— | $1.3M— | |
| Other CF product revenues | $135.9M-12.5% | $237.4M+24.2% | $175.8M-5.9% | $236.1M+20.2% | $155.3M-25.0% | |
| TRIKAFTA/KAFTRIO | $2.35B-7.1% | $2.57B-5.5% | $2.65B+2.7% | $2.55B+4.2% | $2.54B+2.1% | |
| Cost of Sales by Product | ||||||
| Product revenues, net | $160.2M+22.7% | $190.8M+25.2% | $139.6M+6.1% | $140.5M+13.8% | $130.6M+20.0% | |
| Royalty | $232.6M+0.1% | $275.2M+1.5% | $275.2M+5.4% | $267M+7.5% | $232.4M-0.6% | |
| Product revenues, net by Geography | ||||||
| Europe | $950M+14.9% | —— | —— | —— | $826.6M-14.6% | |
| Other | $261M-6.8% | —— | —— | —— | $280.1M+27.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vertex Pharmaceuticals break its business down?
- Vertex Pharmaceuticals (VRTX) reports product revenues, net by product across 5 parts — ALYFTREK, CASGEVY, JOURNAVX, Other CF product revenues and TRIKAFTA/KAFTRIO. Each is extracted from the segment footnotes and tracked over time.
- Where does Vertex Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vertex Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
